RxDoctor Payments Data

David Mushatt, MD

Infectious Disease · New Orleans, LANPI 1235222324

Payments from drug & device makers

$551in general payments, 2019–2025

Across 28 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cormedix Inc.$59
  • Viiv Healthcare Company$58
  • Merck$54
  • Melinta Therapeutics, LLC$49
  • Aurinia Pharma U.S., Inc.$45
  • Paratek Pharmaceuticals, Inc.$44
  • plus $241 from 9 others

What the payments were for

  • Food & beverage$53597%
  • Education$163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$551 in reported general payments places this provider in the 40th percentile of 105 infectious disease providers in Louisiana.

See all infectious disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$19,525
Medicare patients
89
Services billed
180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DescovyEmtricitabine/Tenofov Alafenam112$257,233
IsentressRaltegravir Potassium98$190,338
BiktarvyBictegrav/Emtricit/Tenofov Ala36$154,250
GenvoyaElviteg/Cob/Emtri/Tenof Alafen37$149,007
TivicayDolutegravir Sodium37$109,866
Daptomycin69$88,418
OdefseyEmtricitab/Rilpiviri/Tenof Ala22$85,387
Maraviroc24$57,648
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf12$53,090
JulucaDolutegravir/Rilpivirine14$46,752
Etravirine37$44,365
Darunavir41$37,623
ErtapenemErtapenem Sodium45$26,649
VemlidyTenofovir Alafenamide11$18,458
Meropenem38$15,616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckIsentress$54$190,33898 claims
Viiv Healthcare CompanyTivicay, Juluca$58$156,61851 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 105 infectious disease providers in Louisiana.

Other infectious disease in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →